Cargando…
Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger’s disorder: a 12-week prospective, open-label study
BACKGROUND: Numerous medications have been tested on patients with pervasive developmental disorder not otherwise specified (PDD-NOS) and Asperger’s disorder. Although many of these medications have been demonstrated to be useful, no clear primary treatment for PDD-NOS and Asperger’s disorder has em...
Autores principales: | Miyaoka, Tsuyoshi, Wake, Rei, Furuya, Motohide, Liaury, Kristian, Ieda, Masa, Kawakami, Kazunori, Tsuchie, Keiko, Inagaki, Takuji, Horiguchi, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533891/ https://www.ncbi.nlm.nih.gov/pubmed/23194148 http://dx.doi.org/10.1186/1471-244X-12-215 |
Ejemplares similares
-
Yokukansan promotes hippocampal neurogenesis associated with the suppression of activated microglia in Gunn rat
por: Furuya, Motohide, et al.
Publicado: (2013) -
Morphological features of microglial cells in the hippocampal dentate gyrus of Gunn rat: a possible schizophrenia animal model
por: Liaury, Kristian, et al.
Publicado: (2012) -
Analysis of Copper and Zinc Plasma Concentration and the Efficacy of Zinc Therapy in Individuals with Asperger’s Syndrome, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and Autism
por: Russo, A.J., et al.
Publicado: (2011) -
Fecal Microbiota and Metabolome of Children with Autism and Pervasive Developmental Disorder Not Otherwise Specified
por: De Angelis, Maria, et al.
Publicado: (2013) -
The Diagnosis of “Pervasive Developmental Disorder Not Otherwise Specified”: A Systematic Literature Review
por: Carbone, Agostino, et al.
Publicado: (2023)